Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Diane Hahn

Simon Lawrence Goodman

Francesc Mitjans

Jaume Adan

Kin-Ming Lo

Frank Zenke

Timo Heinrich

Manja Friese-Hamim

Elisabet Rosell

Jaume Piulats

Felix Rohdich

Compounds according to Claim, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.

Pyrrolidinone derivatives as MetAP-2 inhibitors

The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.

Engineered anti-alpha V-integrin hybrid antibodies

The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:

Anti-.alpha.V-integrin monoclonal antibody

Growing community of inventors

Seeheim-Jugenheim, Germany

Diane Hahn